Engineering Human MAIT Cells with Chimeric Antigen Receptors for Cancer Immunotherapy.

Authors

Mikail Dogan, The Jackson LaboratoryFollow
Ece Karhan, The Jackson LaboratoryFollow
Lina Kozhaya, The Jackson LaboratoryFollow
Lindsey Placek, The Jackson LaboratoryFollow
Xin Chen, The Jackson LaboratoryFollow
Mesut Yigit, The Jackson LaboratoryFollow
Derya Unutmaz, The Jackson LaboratoryFollow

Document Type

Article

Publication Date

10-15-2022

Publication Title

Journal of immunology (Baltimore, Md. : 1950)

Keywords

JGM, Antigens, Breast Neoplasms, CD8-Positive T-Lymphocytes, Female, Histocompatibility Antigens Class I, Humans, Immunotherapy, Lymphoma, B-Cell, Minor Histocompatibility Antigens, Mucosal-Associated Invariant T Cells, Receptors, Antigen, T-Cell, Receptors, Chimeric Antigen, Vitamins

JAX Source

J Immunol. 2022;209(8):1523-31.

Volume

209

Issue

8

First Page

1523

Last Page

1531

ISSN

1550-6606

PMID

36165183

DOI

https://doi.org/10.4049/jimmunol.2100856

Grant

This work was supported by National Cancer Institute Grant R21 CA224422 (to D.U.) and The JAX Cancer Center through National Cancer Institute Grant P30 CA034196-33.

Abstract

Engineering immune cells with chimeric Ag receptors (CARs) is a promising technology in cancer immunotherapy. Besides classical cytotoxic CD8

Recommended Citation

Dogan M, Karhan E, Kozhaya L, Placek L, Chen X, Yigit M, Unutmaz D. Engineering Human MAIT Cells with Chimeric Antigen Receptors for Cancer Immunotherapy. J Immunol. 2022;209(8):1523-31.